Kestra Medical stock price target reiterated at $32 by BTIG

BTIG reiterated a Buy and $32 price target on Kestra Medical (KMTS), implying ~66% upside versus the current $19.32 share price, based on 10x BTIG's 12–24 month EV/sales forecast. Kestra reported 59% revenue growth over the last 12 months and a 48.75% gross margin, and Q3 revenue beat by ~7% despite an EPS miss of -$0.61 vs. -$0.42; adjusted EBITDA loss was smaller than expected. Piper Sandler kept an Overweight rating and the company’s cash exceeds debt, supporting BTIG’s view that revenue acceleration and margin expansion are likely as the rental model scales.

Analysis

The scaling of a rental-based cardiac device franchise creates winners beyond the OEM: specialty distributors, telemetry module suppliers, and asset-based lenders will see higher recurring revenue and financing volumes if utilization stabilizes. Conversely, legacy inpatient device vendors that rely on capital sales and implantation services face margin compression as hospitals shift from CAPEX to OPEX and try to consolidate vendor contracts around rental economics.

Near-term catalysts are predominantly commercial and policy-driven rather than clinical: payer contract wins, utilization inflection across large IDNs, or a change in reimbursement policy can move the stock meaningfully within weeks to months; durable margin expansion requires multi-quarter improvement in utilization and lower per-unit service costs. Key tail risks include payer audits or CMS guidance tightening, a competitive low-cost entrant that forces price resets, and single-supplier component shortages that push warranty/service costs higher.

The market consensus appears to price in a smooth ramp of recurring revenue and margin leverage; that understates operational execution risk and float-driven volatility. The optimal way to express conviction is to target asymmetric payoffs that capture upside if rental economics scale while limiting downside from reimbursement or execution shocks. Liquidity is limited, so position sizing and optionality structure should reflect potential wide bid/ask spreads and gap risk on news.

Key Decisions for Investors

• Long KMTS equity (1–1.5% portfolio weight) with a protective 3–6 month put (strike ~10–15% below entry) to capture commercial ramp upside while capping downside; aim for 2–3x return on risk if utilization and payer wins materialize within 6–12 months.
• Buy a 9–18 month call spread on KMTS (debit-funded) rather than outright calls to limit premium exposure; target asymmetric payoff where max loss = premium and potential return ≥2x if margins expand and ARR-like revenue growth sustains.
• Pair trade: Long KMTS / Short MDT (ratio ~1:0.2) for a 12-month horizon to isolate idiosyncratic rental adoption upside while hedging broader medtech cyclicality; cut size if biweekly claims or reimbursement headlines surface.
• Income tactic for existing holders: Sell short-dated OTM covered calls or cash-secured OTM puts on KMTS to monetize near-term optimism and patience for a longer commercial proof period; avoid aggressive short strikes given small-cap gap risk.